The roles and responsibilities of the Qualified Person in the pharmaceutical industry by Pisani, Rachel Cilia et al.
Issue 15  Summer 200944          Journal of the Malta College of Pharmacy Practice
Introduction
Malta’s accession into the European 
Union in May 2004 brought with it a 
number of changes within the local 
pharmaceutical industry. Foremost amongst 
these was the requirement for the holder 
of a manufacturing or import authorisation 
to have permanently and continuous at his 
disposal the services of one or more Qualified 
Persons (QPs).1
QP certification and batch release were 
originally defined approximately a quarter of 
a century ago in Council Directives 75/319/
EEC (Human) and 81/851/EEC (Veterinary), 
which have now been incorporated in 
Directive 2001/83/EC (Human) and 2001/82/
EC (Veterinary), respectively, as amended 
by subsequent Directives.  Currently, no 
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batch of medicinal product may be released 
to the market within the European Union 
(EU), unless a nominated QP has certified 
that it has been manufactured and checked 
in compliance with national and European 
law, and the requirements of the marketing 
authorisation. 
However, the logistics existing in today’s 
pharmaceutical industry are is in stark 
contrast to the situation that existed in the 
seventies, where single-site manufacture was 
the norm. Today’s complexity implies that QP 
overview and batch certification has become 
a much more laborious task, due to mergers 
and acquisitions leading to ‘split-site’ or 
‘multiple-site’ manufacture. 
The Legal Duties of the Qualified Person
The legal duties of the qualified person are 
to ensure that:
•	 Medicinal	products	manufactured	
within the European Union have been 
manufactured and checked within 
the boundaries of national law and 
the requirements of the Marketing 
Authorisation (MA). 
•	 Any	pharmaceutical	imported	from	a	third	
country must have undergone, within 
the EU, a full qualitative analysis, a 
quantitative analysis of at least all the 
active ingredients and all other tests 
necessary to confirm compliance with the 
MA. 
•	 Finally,	the	QP	is	bound	by	law	to	certify	
in a register or equivalent document, 
that the above-mentioned provisions are 
satisfied before the batch is placed on 
the market.
The Routine Duties of the Qualified Person
Placing a medicinal product on the 
market involves various stages from 
development at laboratory scale up to 
commercial manufacture.  
A well planned, organised and 
maintained Quality Management System 
(QMS), as referred to in Article 6 of 
2003/94/EC, is key to ensuring that a 
medicinal product of the required quality, 
safety and efficacy reaches the patient. 
For a product to meet the required 
standards various elements of current Good 
Manufacturing Practices (cGMP) need to be 
in place, including training, documentation 
control, validation, change control, 
maintenance, control of purchasing, and self 
inspection to name but a few. 
Given this plethora of responsibilities, 
in all except small scale operations the QP 
has no alternative but to delegate some or 
all of these routine duties to colleagues. 
Delegation of these duties should be clearly 
defined within the QMS. 
Having said this, it should be specified 
that the legal duties mentioned previously 
may only be delegated to another QP. 
Conversely, sufficiently qualified and trained 
personnel should be designated to perform 
any day-to-day tasks related to ensuring 
adherence to the quality systems in place.
Thus, the critical requirements that a 
QP must take into account when certifying 
batches of medicinal product for release 
include, but are not limited to, the 
following:
•	 Batch	compliance	to	the	provisions	of	the	
MA.
responsibility of the QP and provide every 
support. 
Furthermore the QP must be committed 
to interact with professional colleagues and 
comprehend their contribution and impact 
upon product quality.  Having said this, 
the QP must possess various key attributes 
which facilitate his/her role within the QMS. 
Of special mention are a sound knowledge 
of the laws, authorisations, products and 
processes coupled with experience of 
manufacture and its business requirements. 
On a personal level problem solving 
skills, teambuilding and professionalism 
play a crucial part in executing one’s 
role successfully. Furthermore, active 
collaboration with the company’s senior 
management is imperative, with the latter 
aiding in the implementation, maintenance 
and development of the quality system.
In conjunction, the QP’s relationship 
with Regulatory Authorities is of utmost 
importance in the understanding of all the 
legal and regulatory obligations which his/
her company must fulfill. This must be 
based upon the principles of mutual trust 
and respect for each other’s role in relation 
to patient safety. It is also very important 
that the QP understands the organisational 
structure of the Regulatory Body and its 
operation, together with its key personnel. 
Finally, as outlined in Annex 16 to the EU 
GMP guidelines, “Certification by a Qualified 
Person and Batch Release’, continuous 
training is essential in maintaining 
knowledge and experience current in the 
light of technical and scientific progress. 
Although there are no specific requirements 
regarding the content of the continuous 
training defined in EU legislation, various 
guidelines and Codes of Practice are available 
to give direction to the QP in the execution 
of his/her duties.
Conclusion: a look to the future
The professional aspect of the 
responsibilities of the QP, as outlined above, 
has led to a discussion at European level as 
to whether amendments to Annex 16 should 
grant QP’s greater discretion in dealing with 
one-off minor deviations from the details set 
out in the MA, provided that such deviations 
do not influence the safety or efficacy of the 
product, and the decision whether to release 
the medicinal product notwithstanding such 
deviation is based on principles of quality risk 
management, as outlined in the recent Annex 
20 to the EU GMP guidelines. However it is 
generally accepted that the implementation 
of quality risk management principles will 
require a cultural change in the pharmaceutical 
industry, and in the light of the reticence of 
the competent authorities in certain Member 
States to accept the EMEA proposal, further 
discussion at the highest level is required 
before this principle can be implemented.
More recently, greater emphasis has 
emerged on the role of QPs in the prevention 
of the penetration of counterfeit medicinal 
products in the EU. The latest proposal 
for amendments to Directive 2001/83/EC 
introduces a requirement for features on 
the outer packaging making it possible to 
ascertain the identification, authenticity and 
traceability of medicinal products subject to 
medicinal prescription. The role of the QP in 
this field is being considered so important 
that ensuring the presence of these features 
is being proposed as a new legal duty, one 
which will certainly call upon the professional 
responsibility of Qualified Persons to update 
their knowledge in this field, as befits health 
professionals responsible for ensuring the 
quality, safety and efficacy of medicinal 
products.
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•	 Adherence	to	the	fundamentals	of	cGMP	
as stipulated in Directive 2003/94/EC and 
other relevant regulations.
•	 Validation	of	manufacturing	and	
analytical procedures.
•	 Documentation	and	evaluation	of	any	
deviations or planned changes during 
manufacture.
•	 Adequate	batch	documentation	endorsed	
by authorised staff.
•	 Assurance	of	a	suitable	internal/external	
audit schedule and respective corrective 
and preventive actions.
•	 Consideration	of	factors	that	may	directly	
or indirectly affect the quality of the 
batch in question, such as environmental 
monitoring, calibration and preventative 
maintenance records.
The aforementioned list is not 
exhaustiveand readers are referred to the 
various Codes of Practice listed in the 
Bibliography for further details. 
The Qualified Person: A professional
Directive 2001/83/EC, as amended, 
requires Member States to ensure that the 
duties of QPs are fulfilled by appropriate 
administrative measures or by making them 
subject to a professional code of conduct. 
The latter provision is a clear indication 
of the professional role of the QP, and 
the necessary legislative framework to 
support this status of the QP has recently 
been enacted in Malta, establishing QPs 
as professionals within the Health Care 
Professions Act, under the auspices of the 
Pharmacy Council.
In considering the complexity of the 
roles of QPs discussed previously within 
the sphere of the QMS, team effort is of 
paramount importance. The individuals 
concerned must realise the position and 
